NCT05470582已完成3 期
Randomized, Double-blind, Comparative, Controlled Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old
St. Petersburg Research Institute of Vaccines and Sera4 个研究点 分布在 2 个国家目标入组 1,066 人开始时间: 2021年2月16日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,066
- 试验地点
- 4
- 主要终点
- Change from Baseline seroconversion level
研究概览
简要总结
Comparative trial of tolerability, reactogenicity, safety and immunogenicity of the Flu-M vaccine as compared to the Vaxigrip® vaccine in terms of prevention of influenza in children aged 6 months to 9 years (at the time of the first vaccination).
详细描述
The trial includes 2 stages (stage I, II). At stage I children aged 3-9 years will be included. Based on findings from tolerability and safety assessment in respect of the Flu-M vaccine vs. the Vaxigrip® vaccine for the first 7 days after vaccination of volunteers during Stage I, an intermediate report will be prepared. The report will be submitted to the supervisory executive authorities alongside the notice of commencement of Stage II of the trial - the continuation of trial on children aged 3-9 years and the commencement of trial on children aged between 6 months and 35 months. During Stage II, the trial for Stage I volunteers will continue in full and also children aged between 6 and 35 months will be included in the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 6 Months 至 9 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For volunteers aged 3 to 9 years:
- •Healthy children of both sexes aged 3 to 9 years (3 years 0 months 0 days - 8 years 11 months 30 days);
- •The written and dated informed consent of one of the parents for participation in the trial;
- •For volunteers aged 6 to 35 months:
- •Healthy children of both genders aged 6 to 35 months, inclusive (6 months 0 days - 35 months 30 days);
- •The written and dated informed consent of one of the parents for participation in the trial;
- •The trial subject of the was born full-term, with the Apgar score of 7-10 points.
- •For all volunteers:
- •Ability of a volunteer's parents to fulfill the requirements of the Protocol (i.e. to fill out the Patient Diary, come to visit with the volunteer).
排除标准
- •History of influenza (including in mothers for children aged 6 to 35 months) or previous influenza vaccination during 6 months before the trial;
- •Positive result of the SARS-CoV-2 test;
- •Vaccination of the pregnant woman in the 2nd-3rd trimester (for the age group of 6 - 35 months) with an influenza vaccine;
- •Vaccination with any vaccine less than 30 days before participating in the trial or scheduled vaccination with any vaccine within 30 days after vaccination with the trial vaccines;
- •A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter at the injection site) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination), encephalopathy;
- •Allergic reactions to vaccine components or any previous vaccination;
- •History of allergic reaction to chicken protein;
- •History of cancer, leukemia, tuberculosis, autoimmune diseases;
- •Carriage of HIV, syphilis, hepatitis B and C in the medical history, including by parents;
- •Children who received immunoglobulin products or transfusions of whole blood or its components less than 3 months before the start of the trial;
- •Long-term use (more than 14 days) of any immunomodulating medicines less than 3 months before the start of the trial;
- •Any confirmed or suspected immunosuppressive or immunodeficiency condition;
- •History of chronic diseases of the cardiovascular, bronchopulmonary, endocrine systems, blood in the acute stage (recovery less than 4 weeks before vaccination) or in the decompensation stage;
- •Children with hemophilia who may develop bleeding after intramuscular injection;
- •History of progressive neurological pathology, convulsive syndrome, afebrile convulsions;
- •History of acute infectious diseases (fever ≥ 37.5°С): recovery less than 2 weeks before vaccination;
- •Participation in another clinical trial less than 3 months before the start of the trial;
- •History of mental illness of the child and the volunteer's parents;
- •The history of the volunteer's parent being registered with a tuberculosis dispensary and/or a narcological dispensary;
- •Maternal history of drug use or alcohol abuse during pregnancy and/or breastfeeding;
- •Pronounced congenital malformations in a child;
- •Suspected developmental delay in a child.
结局指标
主要结局
Change from Baseline seroconversion level
时间窗: Days 0 (screening), 28, 56, 180 after vaccination/revaccination
Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) The upper limit of bilateral 95 % CI for the difference between seroconversion levels (seroconversion level reference vaccine - the seroconversion level trial vaccine) should not exceed 10%. Seroconversion ≥ 40%
次要结局
- Change from Baseline Seroconversion rate for each virus strain(Days 0 (screening), 28, 56, 180 after vaccination/revaccination)
- Incidence of immediate adverse events (allergic reactions)(2 hours after vaccination/revaccination)
- Change from Baseline Seroconversion factor(Days 0 (screening), 28, 56, 180 after vaccination/revaccination)
- Change from Baseline Seroprotection rate(Days 0 (screening), 28, 56, 180 after vaccination/revaccination)
- Incidence of local adverse events(Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180)
- Incidence of severe adverse events during the trial(Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180)
- Number of participants with abnormal changes of neurological status(Days 0 (screening), 3, 7, 28, 56)
- Number of participants with abnormal changes in vital signs - Respiratory rate (RR)(Days 0 (screening), 3, 7, 28, 56)
- Incidence of systemic adverse events(Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180)
- Number of participants with abnormal changes in physical examination data(Days 0 (screening), 3, 7, 28, 56)
- Number of participants with clinically significant abnormalities - Complete blood count (CBC)(Days 0 (screening), 3)
- Number of participants with clinically significant abnormalities - Biochemical blood test (BBT)(Days 0 (screening), 3)
- Change from Baseline Geometric mean titer (GMT) of antibodies(Days 0 (screening), 28 after vaccination/revaccination)
- Number of participants with abnormal changes in vital signs - Blood pressure (BP)(Days 0 (screening), 3, 7, 28, 56)
- Number of participants with abnormal changes in vital signs - Heart rate (HR)(Days 0 (screening), 3, 7, 28, 56)
- Number of participants with abnormal changes in vital signs - Body temperature(Day 0 (screening); 10 min before, 20 min and 2 hours after vaccination; days 3, 7, 28, 56)
- Number of participants with clinically significant abnormalities - Urinalysis(Days 0 (screening), 3)
- Number of participants with abnormal changes of total IgE(Days 0 (screening), 3, 56)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.InfluenzaNCT05317767St. Petersburg Research Institute of Vaccines and Sera600
已完成
3 期
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant WomenInfluenza, HumanVaccinesInfection VaccinationNCT05457894St. Petersburg Research Institute of Vaccines and Sera207
已完成
2 期
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza VaccineInfluenza, HumanInfluenza Viral InfectionsVaccine ReactionInfluenzaInfection VaccinationNCT05869201St. Petersburg Research Institute of Vaccines and Sera450
已完成
3 期
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 YearsFlu, HumanInfluenzaNCT05312294St. Petersburg Research Institute of Vaccines and Sera654
已完成
1 期
The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy VolunteersInfluenzaNCT05152017St. Petersburg Research Institute of Vaccines and Sera75